Summary & Overview
CPT 96375: Intravenous Sequential Infusion of a New Drug
Headline: New-Drug Sequential IV Infusion Code Clarified for Clinical and Billing Use
Lead: CPT 96375 designates a sequential intravenous infusion of a new drug given for therapeutic, prophylactic, or diagnostic purposes. The code is relevant across outpatient infusion centers and physician offices and matters for accurate billing when multiple new agents are administered in sequence.
What the code represents and why it matters: CPT 96375 captures the administration of a distinct new intravenous agent as an add-on to an infusion episode. Accurate use of the code affects clinical documentation, claims processing, and appropriate identification of services rendered during infusion encounters. Nationally, consistent application supports clear clinical records and reduces billing disputes tied to sequential drug infusions.
Key payers covered: Analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Overview of what readers will learn: The publication provides a concise explanation of the code’s clinical context and typical sites of service; lists common companion modifiers and related CPT entries; summarizes associated provider taxonomies and common ICD-10 diagnoses that may accompany infusion services; and outlines payer coverage considerations and coding relationships to nearby infusion codes. The piece also flags missing service-line metadata where applicable.
Scope note: The summary is written for a national audience and does not include state-specific policy direction.
CPT Code Overview
CPT 96375 describes an intravenous infusion provided for treatment, prophylaxis, or diagnosis when a new drug is given as a sequential infusion. The code denotes administration of a distinct new therapeutic, prophylactic, or diagnostic agent delivered intravenously following an initial infusion sequence.
Service type: Therapeutic, prophylactic, or diagnostic injection or infusion.
Typical site of service: Infusion setting (e.g., outpatient infusion center or physician office).
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient infusion center for administration of a newly initiated intravenous therapy indicated for treatment, prophylaxis, or diagnosis. The typical workflow: triage and vital signs review; verification of order, consent, and allergy status; intravenous access placement or assessment of existing IV access; preparation of the new drug by pharmacy with documentation of substance/drug name; sequential infusion performed per protocol with monitoring for infusion reactions; post-infusion observation and documentation of drug administered, start/stop times, and patient tolerance. Common presenting problems that may prompt this service include fever, nausea/vomiting, chest pain evaluation, or continuation of long-term drug therapy with a new IV agent. Services occur in an infusion setting such as an outpatient infusion center or physician office and involve clinicians from specialties represented by the associated taxonomies.
Coding Specifications
-
Modifier
59- Distinct Procedural ServiceUse when the intravenous infusion represents a distinct procedural service separate from other services on the same day, indicating a separate anatomic site or a separate session of care.
-
Modifier
76- Repeat Procedure or Service by Same Physician or Other Qualified Health Care ProfessionalUse when the same service (same CPT) is repeated by the same provider on the same day for the same patient.
-
Associated provider taxonomies and specialties:
| Taxonomy Code | Specialty |
|---|---|
207RI0011X | Interventional Cardiology |
207R00000X | Internal Medicine Physician |
207L00000X | Anesthesiology |
Related Diagnoses
-
Z79.899— Other long term (current) drug therapyRelevant when the patient is receiving ongoing medication management and a new intravenous agent is added to long-term therapy.
-
R50.9— Fever, unspecifiedRelevant when the new IV infusion is administered for evaluation or treatment of fever or related infectious/inflammatory conditions.
-
R11.2— Nausea with vomiting, unspecifiedRelevant when IV therapy is used for symptomatic control or hydration due to nausea and vomiting.
-
R07.9— Chest pain, unspecifiedRelevant when IV diagnostic or therapeutic infusions are part of the workup or management of chest pain.
-
I10— Essential (primary) hypertensionRelevant when IV agents are administered for diagnostic or therapeutic purposes in a patient with hypertension, or when blood pressure management impacts infusion decisions.
Related CPT Codes
| CPT Code | Description | Relationship to 96375 |
|---|---|---|
96375 | Intravenous infusion, for treatment, prophylaxis, or diagnosis; new drug add-on – specify substance or drug | Primary code: reports a sequential infusion of a new IV drug as an add-on service. |
96376 | Intravenous infusion, for treatment, prophylaxis, or diagnosis; same drug add-on | Used when an additional sequential infusion of the same drug occurs; may be used together with 96375 when multiple sequential doses of the same agent are given after an initial new drug infusion. |
96366 | Therapeutic, prophylactic or diagnostic nonchemotherapy drug infusion or injection – additional sequential infusion | Represents additional sequential infusions; can be an alternative for non-chemotherapy sequential infusions or used in sequence with 96375 depending on drug classification and payer rules. |
Common usage notes: 96375 is the new drug add-on code; 96376 and 96366 are used for subsequent sequential infusions of the same drug or additional non-chemotherapy infusions respectively. Codes may be reported together in a sequence when clinically appropriate and supported by documentation and payer policy.
National Reimbursement Benchmarks
Medicare's national mean rate for CPT 96375 is substantially lower at $16.37 compared with the BUCA commercial aggregate mean of $27.88, reflecting a gap of $11.51 between the federal payer and the average commercial benchmark. This gap indicates materially lower reimbursement under Medicare versus typical commercial plans.
Dispersion across payers varies: Cigna and UnitedHealth Group show wider spreads (P75–P25 of $16.33 and $15.00 respectively), while Medicare and Aetna are the tightest (P75–P25 of $2.00 and $15.00 respectively — note Aetna's spread is larger than Medicare's). The table and chart below present the full percentile and mean-rate breakdown for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.